ANN ARBOR, MI – January 11, 2021 – Ripple Science was highlighted in the most recent issue of the First Analysis Quarterly Insights as an e-Clinical technology vendor supporting the drive for diversity and accessibility in clinical trials. 

Read the full white paper here

About Ripple Science: Ripple Science aims to reduce clinical trial failures by 50% by adapting sales and marketing automation to accelerate participant recruitment and boost retention.  Additional benefits come from leveraging recruitment and retention data in Ripple to measure what matters and provide actionable insights powered by data science. Ripple is the market-leading SaaS platform used by public and private research organizations in order to provide clinical trial participants a truly great experience across more than 485 studies with over 1 million participant events tracked.

To learn more, please visit: 

Media Contact:

Amanda Holdan-Sinisi, Director of Marketing